Who attended? View the participant list.

Day 1: Hilton Cape Town City Centre
Monday, 29 September 2014

8:30–9:00 a.m. Welcome
Douglas Keene, Vice President, Center for Pharmaceutical Management, MSH
Opening remarks from host country and partner organizations

  • South Africa (Precious Matsoso, Director General, National Department of Health, South Africa)
  • WHO (Dr. Delanyo Dovlo, Director, Health Systems and Services Cluster, Regional Office for Africa)
  • USAID (Anthony Boni)
  • Harvard University (Anita Wagner)
9:00–11:15 a.m. A) UHC and Medicines | Plenary session
Facilitator: Professor Aggrey Ambali, Director, African Science, Technology, and Innovation, NEPAD
Rapporteur: Evans Sagwa, MSH/Namibia
9:00–9:20 a.m. Expanding access to health care and medicines in Southern African countries; UHC aspirational goals (Precious Matsoso, National Department of Health)
9:20–9:40 a.m. Importance of medicines in the health system and UHC; stakeholders and their roles and responsibilities (Kees de Joncheere, World Health Organization)
9:40–10:15 a.m. Panel discussion: Perspectives from three Southern Africa countries in relation to medicines benefits and efforts toward UHC

  • Namibia (Banda Ngaujake and Etienne Coetzee, UHC Committee/Social Security Commission)
  • Zambia (Mpuma Kamanga, Ministry of Health, National Social Health Insurance Coordinator)
  • Zimbabwe (Ropah Hove, Director of Pharmacy Services, MOHCC)
10:15–10:30 a.m. Break
10:30–11:00 a.m. Medicines benefits management: An overview of MSH’s user guide, results of assessment in Namibia, and status of assessment in South Africa (Kwesi Eghan, MSH)
11:00–11:15 a.m. Discussion 
11:15–12:30 p.m. B) Medicines Benefits Design & Management | Plenary session
Facilitator: Pamela Kauseni, Ministry of Finance, Planning & Budgeting, Zambia
Rapporteur: Bada Pharasi, MSH/South Africa
11:15–11:35 a.m. Designing & managing medicines benefits – goals, policy options, ethical considerations (Anita Wagner, Harvard University)
11:35–11:55 a.m. Designing and managing medicines benefits – estimating costs; operational and governance considerations (Anban Pillay, National Department of Health, South Africa)
11:55–12:15 p.m. Designing and managing medicines benefits – experiences and partnerships with the private sector (Roger Wiseman, Liberty Health, South Africa)
12:15–12:30 p.m. Discussion
12:30–1:30 p.m. Lunch Break
1:30–4:45 p.m. Facilitated Group Discussions – Part I
1:30–1:40 p.m.  Introduction Participants will be broken into three small discussion groups for Part I and two for Part II of the facilitated conversations. At each of the discussion centers, each group will discuss an overarching topic and up to three (3) sub-topics. At each center there will be a facilitator and a rapporteur who will serve as group hosts. At 40 or 45 minute intervals, participant groups will move to the next discussion center.Group hosts remain at the same discussion center for all discussion groups, and will summarize the previous discussion to the next group of participants. This ensures input on each topic by all participants, building on each other’s contributions and connections of new ideas across topics in each discussion center. After all rotations, each participant will have had an opportunity to contribute to each topic.The discussion group facilitators and rapporteurs then summarize each of the overarching topics in a plenary session and participants draw conclusions.
1:40–2:20 p.m. Topics B1, B2, and B3
2:20–3:00 p.m. Topics B1, B2, and B3
3:00–3:40 p.m. Topics B1, B2, and B3
B1) How to determine medicines benefits policy and program needs?
Facilitator/presenter: Jane Robertson, WHO
Rapporteur: Milli Reddy, MSH/South Africa

  1. What are the objectives of medicines benefit policies and programs on the path toward UHC?
  2. How do we set priorities for selection of medicines for coverage of populations with different needs, given the competing objectives of availability of quality generic and innovator products, equitable access, appropriate use, and affordable costs?
  3. What are potential unintended impacts of medicines benefits policies and programs?

B2) How can medicines benefits be sustainably and equitably financed?
Facilitator/presenter: Tienie Stander, Hexor, South Africa
Rapporteur: Percy Daames, MSH/South Africa

  1. What information is needed to estimate costs of medicines benefits programs?
  2. What medicines policy and program approaches are needed to efficiently cover medicines for both acute and chronic disease management?
  3. What strategies exist to address the economic, logistic, ethical and other challenges of covering new specialty medicines equitably and sustainably?

B3) What are key aspects of managing a medicines benefits program?
Facilitator/presenter: David Lee, MSH
Rapporteur: Catherine Vialle-Valentin, Harvard University

  1. What functions (e.g., updating formularies according to changing needs; price negotiation; purchasing; contracting with providers and suppliers; claims processing; payment; and others) are required to manage a medicines benefits program?
  2. What human and technical (including information technology) resources are needed to execute these functions?
  3. What governance and administrative structures are needed to manage a medicines benefits program?
3:40–4:00 p.m. Break
4:00–4:45 p.m. Facilitated Group Discussions SummaryFacilitators/presenters: Break-out group facilitatorsRapporteurs: Break-out group rapporteurs

  • Break-out group reports (10 minutes for each of three groups)
  • Plenary discussion of key points on medicines benefits design and management
4:45–5:45 p.m. C) Information for decision making | Plenary session
Facilitator: Kofi Aboagye-Nyame, MSH
Rapporteur: Stephanie Berrada, MSH/South AfricaTo ensure wise use of limited resources, emerging and expanding insurance schemes must monitor what they spend money on, and how much money they are spending. Medicines are key factors for achieving the goals of UHC, and the main reasons for inefficiency in spending. It is therefore crucial to monitor key indicators of medicines in health systems using the existing data and to strive toward information technology that facilitates the processes.
4:45–5:05 p.m. Working towards generating information routinely for medicines benefits management – A system framework (Dennis Ross-Degnan, Harvard University)
5:05–5:25 p.m. The critical role of evolving information systems and the need for standardized coding – An example (Christo Rademan, Mediscor, South Africa)
5:25–5:45 p.m. Discussion
Close of Day 1

Day 2: Hilton Cape Town City Centre
Tuesday, 30 September 2014

8:15–8:30 a.m. Re-cap of Day 1
8:30–9:30 a.m.  Multiple-stakeholder partnerships for medicines benefits in moving towards UHC  Panel Session
Facilitator: David Lee, MSH
Rapporteur: Jafary Liana, MSH/TanzaniaDiscussants:


9:30–12 noon Facilitated Group Discussions – Part II
9:30–10:15 a.m. Topics C1 and C2
10:15–11:00 a.m. Topics C1 and C2
C1) What information is needed to inform medicines benefits decisions?
Facilitator/presenter: Anita Wagner, Harvard University
Rapporteur: Stephanie Berrada, MSH/South Africa

  1. What are key performance indicators of medicines benefits from different stakeholders’ perspectives?
  2. How can indicators be created using existing data in countries and systems?
  3. What are successes and challenges in using existing data to inform medicines benefit design, implementation, and adaptation?

C2) What characteristics of systems are needed to generate information for medicines benefits policy and program decisions?
Facilitator/presenter: Ricardo Kettledas, National Department of Health, South Africa
Rapporteur: Katelyn Payne, MSH

  1. Which elements are crucial to capture in evolving care delivery and financing information systems for managing medicines benefits?
  2. How do current or proposed information systems facilitate generating information for medicines benefit decisions?
  3. What technical and human resources as well as governance approaches are needed to facilitate use of information from systems to inform medicines benefits?
11:00–11:15 a.m. Break
11:15–12 noon Facilitated Group Discussions Summary
Facilitators/presenters: Break-out group facilitators
Rapporteurs: Break-out group rapporteurs

  • Break-out group reports (10 minutes for each of two groups)
  • Plenary discussion of key points on medicines benefits design and management
12:00–1:00 p.m. Closing and farewell
Facilitator: Gilles Forte, WHO
Rapporteur: Catherine Vialle-Valentin, Harvard UniversityCountry response:

  • Representatives of each of the eight southern African countries (Lesotho, Malawi, South Africa, Namibia, Swaziland, Botswana, Zambia, Zimbabwe) participating in the meeting will share their thoughts on the most important points learned at the meeting and what would be needed to achieve the objectives of medicines benefits policies on the path to UHC in their countries

Next steps:
Speaker: Douglas Keene, MSH

1:00–2:00p.m. Lunch Break
Close of Day 2

Leave a Reply

Your email address will not be published. Required fields are marked *